EMA to Review New Safety Data on Alzheimer’s Drug Leqembi

The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the European Union. Lecanemab is indicated for treating mild cognitive impairment and early Alzheimer’s disease. It is intended for patients with one or no copy of …
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy
Skip to content